Yazar "Soysal, Teoman" seçeneğine göre listele

Listeleniyor 1 - 6 / 6
  • [ X ]
    Öğe
    Acute colitis presenting with hematochezia in a patient with chronic myeloid leukemia during dasatinib therapy
    (Aves, 2014) Eskazan, Ahmet Emre; Hatemi, Ibrahim; Aydin, Seniz Ongoren; Ar, Muhlis Cem; Soysal, Teoman
    [Abstract Not Available]
  • [ X ]
    Öğe
    Dasatinib May Override F317L BCR-ABL Kinase Domain Mutation in Patients with Chronic Myeloid Leukemia
    (Galenos Yayincilik, 2013) Eskazan, Ahmet Emre; Soysal, Teoman
    [Abstract Not Available]
  • Küçük Resim
    Öğe
    A multi-center study on the efficacy of eltrombopag in management of refractory chronic immune thrombocytopenia: A real-life experience
    (Turkish Society of Hematology, 2019) Çekdemir, Demet; Güvenç, Serkan; Özdemirkıran, Füsun Gediz; Eser, Ali; Toptaş, Tayfur; Özkocaman, Vildan; Şahin, Handan Haydaroǧlu; Turak, Esra Ermiş; Esen, Ramazan; Cömert, Melda; Sadri, Sevil; Aslaner, Müzeyyen; Uncu Ulu, Bahar; Bapur, Derya Selim; Alacacıoğlu, İnci; Aydın, Demet; Tekinalp, Atakan; Namdaroǧlu, Sinem; Ceran, Funda; Tarkun, Pınar; Kiper, Demet; Çetiner, Mustafa; Yenerel, Mustafa Nuri; Demir, Ahmet Muzaffer; Yılmaz, Güven; Terzi, Hatice; Atilla, Erden; Malkan, Ümit Yavuz; Acar, Kadir; Öztürk, Erman; Tombak, Anıl; Sunu, Cenk; Salim, Ozan; Alayvaz, Nevin; Sayan, Özkan; Ozan, Ülkü; Ayer, Mesut; Gökgöz, Zafer; Andıç, Neslihan; Kızılkılıç, Ebru; Noyan, Figen; Özen, Mehmet; Tanrıkulu, Funda Pepedil; Alanoǧlu, Gü̧chan; Özkan, Hasan Atilla; Aslan, Vahap; Çetin, Güven; Erikçi, Alev Akyol; Deveci, Burak; Dursun, Fadime Ersoy; Dermenci, Hasan; Aytan, Pelin; Gündüz, Mehmet; Karakuş, Volkan; Özlü, Can; Demircioğlu, Sinan; Yanar, Olga Meltem Akay; Özatlı, Düzgün; Ündar, Levent; Tiftik, Eyüp Naci; Sucak, Ayhan Gülsan Türköz; Haznedaroğlu, İbrahim Celalettin; Özcan, Muhit; Şencan, Mehmet; Tombuloğu, Murat; Özet, Gülsüm Gulistan; Bilgir, Oktay; Turgut, Burhan; Özcan, Mehmet Ali; Payzın, Kadriye Bahriye; Sönmez, Mehmet; Ayyıldız, Orhan; Dal, Mehmet Sinan; Ertop, Şehmus; Turgut, Mehmet; Soysal, Teoman; Kaya, Emin; Ünal, Ali Ekrem; Pehlivan, Mustafa; Atagündüz, Işık Kaygusuz; Fıratlı, Tülin Tuğlular; Saydam, Güray; Küçükkaya, Reyhan Diz
    Objective: The aim of the present study was to evaluate the efficacy and safety of eltrombopag, an oral thrombopoietin receptor agonist, in patients with chronic immune thrombocytopenia (ITP). Materials and Methods: A total of 285 chronic ITP patients (187 women, 65.6%; 98 men, 34.4%) followed in 55 centers were enrolled in this retrospective cohort. Response to treatment was assessed according to platelet count (/mm3) and defined as complete (platelet count of >100,000/mm3), partial (30,000-100,000/mm3 or doubling of platelet count after treatment), or unresponsive (<30,000/mm3). Clinical findings, descriptive features, response to treatment, and side effects were recorded. Correlations between descriptive, clinical, and hematological parameters were analyzed. Results: The median age at diagnosis was 43.9±20.6 (range: 3-95) years and the duration of follow-up was 18.0±6.4 (range: 6-28.2) months. Overall response rate was 86.7% (n=247). Complete and partial responses were observed in 182 (63.8%) and 65 (22.8%) patients, respectively. Thirty-eight patients (13.4%) did not respond to eltrombopag treatment. For patients above 60 years old (n=68), overall response rate was 89.7% (n=61), and for those above 80 years old (n=12), overall response rate was 83% (n=10). Considering thrombocyte count before treatment, eltrombopag significantly increased platelet count at the 1st, 2nd, 3rd, 4th, and 8th weeks of treatment. As the time required for partial or complete response increased, response to treatment was significantly reduced. The time to reach the maximum platelet levels after treatment was quite variable (1-202 weeks). Notably, the higher the maximum platelet count after eltrombopag treatment, the more likely that side effects would occur. The most common side effects were headache (21.6%), weakness (13.7%), hepatotoxicity (11.8%), and thrombosis (5.9%). Conclusion: Results of the current study imply that eltrombopag is an effective therapeutic option even in elderly patients with chronic ITP. However, patients must be closely monitored for response and side effects during treatment. Since both response and side effects may be variable throughout the follow-up period, patients should be evaluated dynamically, especially in terms of thrombotic risk factors.
  • [ X ]
    Öğe
    Retrospective Evaluation of Patients Treated with Dasatinib for Philadelphia Positive Leukemias: Turkish Experience of 16 Months
    (Akad Doktorlar Yayinevi, 2009) Saydam, Gueray; Haznedaroglu, Ibrahim C.; Temiz, Yesim; Soysal, Teoman; Sucak, Gulsan; Tombuloglu, Murat; Ozdogu, Hakan
    This retrospective study was conducted on 114 CML patients with a mean treatment duration of 7.94 +/- 4.53 months. Disease status distribution among patients was 78.1% in chronic, 7.9% in accelerated, 14% in blastic phases. The last imatinib doses in chronic, accelerated and blastic phases were 609.72 +/- 171.29, 714.29 +/- 106.90, and 569.23 +/- 160.13, respectively. Complete hematologic response was 66.3% and 44.4% in chronic and accelerated phases, respectively. Molecular response was evaluated by bcr/abl transcript levels in RT-PCR. Complete molecular response was 27.0% in chronic, 11.1% in accelerated and 18.8% in blastic phases. Of 99 patients 77 (77.8%) were alive. 16th month-OS for 99 patients was 78% in Kaplan-Meier survival analysis. No adverse event was reported in 69.2% of patients, whereas disease progression and grade 1-2 myelosupression were the most frequently reported events. Most patients had complete hematological response. Dasatinib treatment was well-tolerated and resulted in favorable outcomes with mostly mild side effects.
  • [ X ]
    Öğe
    Simultaneous Detection of B-Cell Chronic Lymphocytic Leukemia and Colon Adenocarcinoma in the Same Mesenteric Lymph Node
    (Galenos Yayincilik, 2013) Eskazan, Ahmet Emre; Berk, Selin; Ozden, Ferhat; Erdamar, Sibel; Tuzuner, Nukhet; Soysal, Teoman
    [Abstract Not Available]
  • [ X ]
    Öğe
    Two Cases of Autoimmune Hemolytic Anemia Secondary to Brucellosis: A Review of Hemolytic Disorders in Patients with Brucellosis
    (Japan Soc Internal Medicine, 2014) Eskazan, Ahmet Emre; Dal, Mehmet Sinan; Kaya, Safak; Dal, Tuba; Ayyildiz, Orhan; Soysal, Teoman
    Brucellosis is a worldwide zoonotic disease associated with hemolytic complications, including thrombotic microangiopathy (TMA) and hemolytic anemia. Autoimmune hemolytic anemia (AIHA) is a rare clinical presentation of this disease. In this report, we describe the cases of two patients with brucellosis who presented with Coombs-positive AIHA. We also include a review of the literature on the hemolytic complications of brucellosis. Both patients were successfully treated with a combination of doxycycline and rifampicin in addition to steroids. In the medical literature, there are several cases of TMA associated with brucellosis, although only a few cases of Coombs test-positive AIHA have been reported. Antibiotic therapy is the mainstay of treatment, and the selection of antibiotics and duration of treatment do not differ between brucellosis patients with and without hemolysis. Although rare, the potential for brucellosis should always be kept in mind in patients who present with hemolysis, especially those living in areas where brucellosis is endemic.